Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Theralase Technologies Inc. > 1 of 2 options for Breakthrough designation application
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(12061)
•••
Comment by ScienceFirston Nov 24, 2022 6:26pm
178 Views
Post# 35126512

RE:RE:RE:RE:RE:RE:RE:RE:1 of 2 options for Breakthrough designation application

RE:RE:RE:RE:RE:RE:RE:RE:1 of 2 options for Breakthrough designation applicationRobertshaw ... You've been whining about dilution and stupid management for years.  Big impressie posts!  Wow!  

I'll let you calculate what the selection of an indication that avoids a Ph. III saves us, what Breakthrough designation could save us and what Accelerated Approval could also save us.  And what PDT as a technology could saves us.

Then we'll see how credible are your repetitive statements.  And if you have this ability to appreciate what some do for you.  

______________________




StevenBirch wrote:Yes a halt would be great. It hasn't been TLT's style but the type of news we are waiting/hoping for would be their biggest news to date.

I doubt the management has that wit. 

robertshaw - (11/24/2022 4:53:04 PM)
RE:RE:RE:RE:RE:RE:RE:1 of 2 options for Breakthrough designation application
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities